LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000179.3:c.4031_4039del
MSH6
· NP_000170.1:p.(Val1345_Ala1347del)
· NM_000179.3
GRCh37: chr2:48033946 ACTGTAGATG>A
·
GRCh38: chr2:47806807 ACTGTAGATG>A
Gene:
MSH6
Transcript:
NM_000179.3
Final call
VUS
PM2 supporting
Variant details
Gene
MSH6
Transcript
NM_000179.3
Protein
NP_000170.1:p.(Val1345_Ala1347del)
gnomAD AF
2.483250475542466e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PM2 supporting: gnomAD v4.1 total allele frequency is 2.48325e-06, below the VCEP threshold of 0.00002.
Final determination:
Because PM2 supporting alone satisfies no pathogenic or benign rule in the MSH6 VCEP Version 2.0 framework, the variant remains a VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: the variant is an in-frame 9-bp exon 10 deletion, whereas the VCEP PVS1 rule names nonsense, frameshift, splice, large-alteration, or RNA-confirmed aberration paths. |
cspec
vcep_pvs1_decisiontree_mmr
vcep_vcep_pilot_variants_mmr
pvs1_variant_assessment
|
| PS1 | N/A | Not applicable: the variant is an in-frame three-residue deletion, whereas PS1 requires a predicted missense substitution or the same non-canonical splice nucleotide. |
cspec
|
| PS2 | Not assessed | Not assessed: no documented de novo result, parental testing, maternity/paternity confirmation, or VCEP de novo point assignment is available. |
cspec
|
| PS3 | Not assessed | Not assessed: no variant-specific functional assay result or calibrated functional odds were identified for the in-frame p.Val1345_Ala1347del deletion. |
cspec
vcep_functional_assay_svi_documentation_mmr
vcep_functional_assay_flowchart
PMID:30504929
PMID:31965077
|
| PS4 | N/A | Not applicable: the MSH6 VCEP explicitly designates PS4 as Not Applicable, regardless of the available literature or case-control evidence. |
cspec
|
| PM1 | N/A | Not applicable: the MSH6 VCEP explicitly excludes PM1 because no recognized hotspot or domain-based PM1 route is approved for classification. |
cspec
vcep_mmr_functional_domains
|
| PM2 | Met | Met at Supporting: gnomAD v4.1 total AF is 2.48325e-06, below the PM2 threshold of <0.00002 (<1 in 50,000 alleles). |
cspec
gnomad_v4
|
| PM3 | Not assessed | Not assessed: no affected-proband observation with a pathogenic MSH6 variant in confirmed trans phase and no VCEP PM3 point total are documented. |
cspec
|
| PM4 | N/A | Not applicable: the MSH6 VCEP explicitly designates PM4 as Not Applicable for this framework. |
cspec
|
| PM5 | N/A | Not applicable: the target is an in-frame deletion, while PM5 requires a missense change and a different pathogenic or likely pathogenic missense change at the same residue. |
cspec
pm5_candidates
|
| PM6 | N/A | Not applicable: the MSH6 VCEP specification explicitly marks PM6 as Not Applicable. |
cspec
|
| PP1 | Not assessed | Not assessed: no pedigree segregation data, informative meioses, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds. |
cspec
|
| PP2 | N/A | Not applicable: the MSH6 VCEP explicitly states that the low rate of benign missense variation PP2 rule does not apply. |
cspec
|
| PP3 | N/A | Not applicable: the variant is an in-frame deletion, outside PP3's missense or non-canonical splice-nucleotide scope, regardless of the available SpliceAI score. |
cspec
|
| PP4 | Not assessed | Not assessed: no patient-specific MSI, tumor-genome, or MMR-protein-expression result is available to compare with the VCEP's PP4 tumor thresholds. |
cspec
vcep_table_for_cmmrd_diagnosis
vcep_vcep_pilot_variants_mmr
|
| PP5 | N/A | Not applicable: the MSH6 VCEP explicitly designates PP5 as Not Applicable, and no variant-specific paper evidence overrides that rule. |
cspec
|
| BA1 | Not met | Not met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BA1 threshold of ≥0.0022 (0.22%). |
cspec
gnomad_v4
|
| BS1 | Not met | Not met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BS1 interval beginning at ≥0.00022 (0.022%). |
cspec
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no qualifying in-trans co-occurrence, phase confirmation, cancer-age condition, or CMMRD-status documentation is available. |
cspec
|
| BS3 | Not assessed | Not assessed: no variant-specific proficient-function result or calibrated functional odds were identified for the in-frame p.Val1345_A1347del deletion. |
cspec
vcep_functional_assay_svi_documentation_mmr
vcep_functional_assay_flowchart
PMID:30504929
PMID:31965077
|
| BS4 | Not assessed | Not assessed: no non-segregating carriers, informative pedigree, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds. |
cspec
|
| BP1 | N/A | Not applicable: the MSH6 VCEP excludes BP1, and the target is an in-frame deletion rather than a missense variant. |
cspec
|
| BP2 | N/A | Not applicable: the MSH6 VCEP specification explicitly marks BP2 as not applicable. |
cspec
|
| BP3 | N/A | Not applicable: the MSH6 VCEP explicitly designates BP3 as Not Applicable for this framework. |
cspec
|
| BP4 | N/A | Not applicable: the variant is an in-frame deletion, outside BP4's missense or intronic/synonymous scope, so SpliceAI 0.102 cannot establish BP4. |
cspec
|
| BP5 | Not assessed | Not assessed: no patient-specific tumor count or MSS, MMR-protein, BRAF V600E, or MLH1-methylation result is available for the BP5 requirements. |
cspec
|
| BP6 | N/A | Not applicable: the MSH6 VCEP explicitly designates BP6 as Not Applicable under its version 2.0 specification. |
cspec
|
| BP7 | N/A | Not applicable: the variant is an exonic in-frame deletion, not a synonymous or intronic variant at or beyond the BP7 -21/+7 boundary. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.